Everence Capital Management Inc. Sells 2,778 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Everence Capital Management Inc. decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 48.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,920 shares of the medical research company's stock after selling 2,778 shares during the quarter. Everence Capital Management Inc.'s holdings in IQVIA were worth $574,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. GAMMA Investing LLC lifted its holdings in IQVIA by 27.7% during the 4th quarter. GAMMA Investing LLC now owns 1,406 shares of the medical research company's stock worth $276,000 after purchasing an additional 305 shares in the last quarter. Versant Capital Management Inc lifted its holdings in shares of IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after buying an additional 93 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock valued at $437,378,000 after acquiring an additional 583,396 shares during the period. Principal Financial Group Inc. grew its stake in IQVIA by 0.8% during the third quarter. Principal Financial Group Inc. now owns 209,021 shares of the medical research company's stock valued at $49,532,000 after acquiring an additional 1,750 shares in the last quarter. Finally, Oddo BHF Asset Management Sas bought a new stake in IQVIA during the 3rd quarter worth approximately $2,771,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently commented on IQV. Redburn Atlantic started coverage on shares of IQVIA in a research report on Monday, October 14th. They set a "buy" rating and a $276.00 price target for the company. Leerink Partners restated an "outperform" rating and set a $248.00 target price (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Stephens started coverage on IQVIA in a report on Friday, December 20th. They issued an "overweight" rating and a $250.00 price target on the stock. Evercore ISI cut their price objective on IQVIA from $270.00 to $265.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Finally, JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $279.00 to $240.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $255.82.

IQVIA Trading Up 1.2 %

IQVIA stock traded up $2.27 during trading hours on Friday, reaching $197.39. The stock had a trading volume of 849,619 shares, compared to its average volume of 776,209. The company has a fifty day simple moving average of $202.86 and a 200-day simple moving average of $222.07. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The stock has a market cap of $35.83 billion, a PE ratio of 25.90, a PEG ratio of 2.05 and a beta of 1.49. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.